Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Authors :: Hakan Cinemre
Veli Berk
Cemil Bilir
Ebru Karcı
Ahmet Bilici
Pınar Dal
Ozan Yazici
Nuri Karadurmus
Esin Oktay
Yasar Yildiz
Kezban Nur Pilanci
Ozgur Tanriverdi
Erkan Arpaci
Ibrahim Petekkaya
Ceyhun Varim
Erdinc Nayir
Mahmut Ucar
Suleyman Temiz
Goksen Inanc Imamoglu
Ibrahim Yildiz
Zonguldak Bülent Ecevit Üniversitesi
Bilir, C
Yildiz, I
Bilici, A
Ucar, M
Berk, V
Yildiz, Y
Yazici, O
Imamoglu, GI
Karadurmus, N
Pilanci, KN
Arpaci, E
Tanriverdi, O
Karci, E
Temiz, S
Nayir, E
Oktay, E
Dal, P
Petekkaya, I
Varim, C
Cinemre, H
Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
Bilir, Cemil
Varım, Ceyhun
Cinemre, Hakan
Source :: Cancer investigation. 35(4)
Publication Year :: 2017
Abstract: WOS: 000399505100004 PubMed ID: 28333566 Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.

Tools